Use of infliximab in pyoderma gangrenosum.
A 57-year-old man, with a 2-year history of Crohn's disease, presented with a rapidly progressive abdominal ulcer. It was clinically and histologically consistent with pyoderma gangrenosum but it did not respond to either high-dose oral prednisolone or intravenous hydrocortisone. Infliximab resulted in an early, dramatic and sustained improvement. His bowel symptoms, which flared a few weeks prior to the onset of pyoderma gangrenosum, only partially improved. Despite six infliximab infusions, the inflammatory bowel disease is poorly controlled, whereas the pyoderma gangrenosum remains healed.
Hewitt
Daniel
D
Department of Dermatology, Royal Perth Hospital, Western Australia, Australia. dthewitt@gmail.com
Tait
Clare
C
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome; D014945:Wound Healing
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D013256:Steroids; D000069285:Infliximab